医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Nihon Kohden Launches Neuropack® S3 Electrodiagnostic System Offering Unparalleled Clean Waveforms

2019年05月02日 AM02:23
このエントリーをはてなブックマークに追加


 

IRVINE, Calif.

Nihon Kohden, a U.S. market leader in precision medical products and services, today announced the launch of its Neuropack S3 electrodiagnostic (EDX) system, an advanced multimodality platform for neurodiagnostic procedures. Featuring the company’s latest-generation amplifiers and signal processing technology, the Neuropack S3 is designed to offer high-quality EDX studies while minimizing footprint and improving portability.

The Neuropack S3 system was developed to be flexible enough for use in both hospitals and private practices to conduct electromyography, nerve conduction studies, evoked potentials, and other diagnostic procedures. The system includes a built-in intelligent stimulation artifact filter, which allows clinicians to improve NCS waveforms in real time and further improves the quality and clarity of signals from Nihon Kohden’s industry-leading amplifiers.

“At Nihon Kohden, we pride ourselves in providing unsurpassed quality and reliability of the signal quality from our amplifiers,” said John Korney, vice president, marketing, Nihon Kohden America. “But we are not willing to rest on our current successes. We continue to improve our technology, and every advancement we make is designed to help clinicians make decisions faster and easier.”

The Neuropack S3 exceeds the performance of earlier-generation EDX systems by providing exceptional signal data quality with input box options for 2 or 4 channels, Hz and an 18-bit analog-to-digital converter.

All Neuropack S3 recordings are captured and stored locally on the PC and through Nihon Kohden’s Neuroworkbench application, and can be set to automatically transfer to short- and long-term storage locations. Clinicians can schedule, review, and create reports from other PCs connected to the Neuroworkbench database. Optional software customizations include autostoring up to 10 minutes of raw EMG data per site, allowing full playback review of each monitored muscle.

The Neuropack S3 comes in standard desktop and laptop models, which revolutionizes the portability of EDX systems by offering a non-cart option that packs up and transports in a shoulder carry bag. The lightweight, slim design of the Neuropack S3 gives clinicians more space in patient exam rooms and enables them to quickly get comfortable with the technology. In addition, clinicians can choose from three stimulator models, each with unique ergonomic designs, to find the right handheld device for their comfort and needs.

About Nihon Kohden Corporation

Founded in Japan in 1951, Nihon Kohden is a leading manufacturer, developer and distributor of medical electronic equipment, with subsidiaries in the U.S., Europe and Asia. The company’s products are now used in more than 120 countries, and it is the largest supplier of electroencephalography products worldwide. A pioneer in transformational healthcare technology, Nihon Kohden has envisioned, designed and produced revolutionary devices, such as pulse oximeters, arrhythmia analysis, low-invasive blood volume monitoring and wireless patient monitoring. In the U.S., the company is a trusted source for patient monitoring, sleep assessment, neurology and cardiology instrumentation solutions, and has been rated No. 1 in patient monitoring or telemetry for more than 10 consecutive years (MD Buyline). For more information, visit us.nihonkohden.com.

MD Buyline is a registered service mark of MD Buyline.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190501005828/en/

CONTACT

Julie Johnson
Senior Director, Communications and Public Relations
949-238-4869
Julie_Johnson@NihonKohden.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 2019年台湾医疗科技展展商简介
  • Alpha Holdings Comments on OncoSec’s Inability to Defend China Grand Takeover
  • Sensor Electronic Technology Obtains Permanent Injunction Against U.S. UV LED Companies
  • LYNPARZA® (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer
  • AJC Organized the ASEAN Services Trade Forum in Tokyo to Discuss the Emerging Demands for Health and Social Services in ASEAN and Its Investment Opportunities